Transmitting information to us by e-mail unilaterally does not establish an attorney-client relationship or impose an obligation on either the law firm or even the receiving lawyer to keep the transmitted information confidential. By clicking "OK", you acknowledge that we have no obligation to maintain the confidentiality of any information you submit to us unless we already represent you or unless we have agreed to receive limited confidential material/information from you as a prospective client. Thus, if you are not a client or someone we have agreed to consider as a prospective client, information you submit to us by e-mail may be disclosed to others or used against you. If you would like to discuss becoming a client, please contact one of our attorneys to arrange for a meeting or telephone conference. If you wish to disclose confidential information to a lawyer in the firm before an attorney-client relationship is established, the protections that the law firm will provide to such information from a prospective client should be discussed before such information is submitted. Thank you for your interest in Goodwin Procter.

Zelos Therapeutics Inc. Completes Series B Financing

Related Content

Washington Becomes First State to Adopt Filing Requirements for HSR-Reportable Transactions Outside of Healthcare

Charting a Conditional Approval Pathway for Rare Disease Drugs – A Top Priority for a Revamped FDA?

Five Trends Reshaping Pharmaceutical Manufacturing Partnerships

Celltrion Adalimumab Biosimilar Granted Interchangeability Designation

FDA to Phase Out Animal Testing for Monoclonal Antibodies and Other Drugs

Life Sciences Companies Must Navigate the DOJ Data Rule

FDA Approves Biocon Biologics’ Bevacizumab Biosimilar

Teva and Samsung Bioepis Announce U.S. Launch of EPYSQLI® (eculizumab-aagh), a SOLIRIS® Biosimilar

Goodwin’s Israel Practice Highly Ranked by Chambers and Israel Desks

SpringWorks Therapeutics To Be Acquired By Merck KGaA, Darmstadt, Germany For $3.9 Billion

Goodwin Tops the Q1 2025 M&A and Private Equity League Tables

Goodwin Guides Syneron Bio on Strategic Collaboration with AstraZeneca for $75 Million and up to $3.4 Billion in Milestones

Goodwin Represents VelaVigo on $440 Million Second Out-Licensing Deal of a First-in-Class Bi-specific Antibody

Brink Therapeutics Raises €3.5 Million

Radiopharmaceuticals M&A to go Nuclear over Production Demand, Novel Drugs (Mergermarket)

Boston Forum: Merger Control & Competition in Life Sciences

Life Sciences